Annual Report Details Strategic Shifts, IRA Impact, and Key Litigation for 2025
BMY sits 43% above its 52-week low of $42.52 on light trading volume (0.2× avg).
Summary
Bristol Myers Squibb's 2025 annual report details a new U.S. Government Agreement with significant pricing concessions, the confirmed impact of the Inflation Reduction Act on key product revenues, and an unfavorable court ruling in the Celgene CVR litigation, alongside the positive financial impact of fully amortized intangible assets.
Key Events · Corporate Governance and Compliance · BMY
-
U.S. Government Agreement Announced
In December 2025, BMS entered into an agreement with the U.S. government, agreeing to provide Eliquis for free to Medicaid, donate Eliquis API, offer ~80% discounts on Sotyktu, Zeposia, Reyataz, Baraclude, and Orencia for cash-paying patients, and adopt a balanced pricing approach for new launches. In return, BMS receives U.S. tariff relief until January 2029 and will not be subject to future U.S. pricing mandates.
-
Inflation Reduction Act (IRA) Pricing Impacts Confirmed
The HHS announced 'maximum fair prices' for Eliquis (effective Jan 1, 2026) and Pomalyst (effective Jan 1, 2027). Orencia was selected for price negotiation starting in 2028. BMS has filed a petition for certiorari at the Supreme Court challenging the IRA's constitutionality after lower court affirmations.
-
Celgene CVR Litigation Update
In December 2025, the court denied BMS's motion to dismiss in substantial part in the Celgene CVR litigation, finding the plaintiff to be the successor trustee. This ongoing lawsuit involves claims of alleged breaches of the CVR Agreement with a potential $6.4 billion obligation.
-
Significant Reduction in Amortization Expense
Amortization of acquired intangible assets decreased by $5.6 billion (63%) in 2025, primarily due to the full amortization of Revlimid's acquired marketed product right in Q4 2024 and Pomalyst's in Q4 2025. This significantly improves future earnings.
Analysis · BMY · Life Sciences
Bristol Myers Squibb's annual report provides a comprehensive overview of its 2025 performance and future outlook, highlighting significant strategic and regulatory developments. The company's proactive U.S. Government Agreement, while offering some tariff relief and exemption from future pricing mandates, involves substantial concessions like providing Eliquis free to Medicaid and offering deep discounts on other key products. This, coupled with the confirmed impact of the Inflation Reduction Act on Eliquis, Pomalyst, and future Orencia pricing, signals ongoing revenue pressures. The update on the Celgene CVR litigation, where the court denied BMS's motion to dismiss in substantial part, represents a material contingent liability. However, the full amortization of Revlimid and Pomalyst acquired product rights is a significant positive for future earnings, reducing a major expense. Investors should monitor the ongoing IRA litigation, the CVR lawsuit, and the commercial performance of new launches against these pricing headwinds.
At the time of this filing, BMY was trading at $60.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $124.1B. The 52-week trading range was $42.52 to $63.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.